IL296701A - Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum - Google Patents
Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serumInfo
- Publication number
- IL296701A IL296701A IL296701A IL29670122A IL296701A IL 296701 A IL296701 A IL 296701A IL 296701 A IL296701 A IL 296701A IL 29670122 A IL29670122 A IL 29670122A IL 296701 A IL296701 A IL 296701A
- Authority
- IL
- Israel
- Prior art keywords
- ofatumumab
- treatment
- cell
- patients
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169007 | 2020-04-09 | ||
| EP20176057 | 2020-05-22 | ||
| US202063076628P | 2020-09-10 | 2020-09-10 | |
| US202163166054P | 2021-03-25 | 2021-03-25 | |
| PCT/EP2021/059285 WO2021204994A1 (en) | 2020-04-09 | 2021-04-09 | Ofatumumab for treating ms while maintaining serum igg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296701A true IL296701A (en) | 2022-11-01 |
Family
ID=75362645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296701A IL296701A (en) | 2020-04-09 | 2021-04-09 | Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230151106A1 (https=) |
| EP (3) | EP4707302A2 (https=) |
| JP (2) | JP7794757B2 (https=) |
| KR (1) | KR20220166827A (https=) |
| CN (1) | CN115427068A (https=) |
| AU (1) | AU2021253674A1 (https=) |
| BR (1) | BR112022019038A2 (https=) |
| CA (1) | CA3176574A1 (https=) |
| DE (1) | DE202021004005U1 (https=) |
| IL (1) | IL296701A (https=) |
| MX (1) | MX2022012600A (https=) |
| WO (1) | WO2021204994A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| WO2012018704A1 (en) * | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2748198A2 (en) * | 2011-09-27 | 2014-07-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| LT3733712T (lt) * | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| MX2022003010A (es) * | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) * | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2021
- 2021-04-09 EP EP25215090.9A patent/EP4707302A2/en active Pending
- 2021-04-09 MX MX2022012600A patent/MX2022012600A/es unknown
- 2021-04-09 DE DE202021004005.6U patent/DE202021004005U1/de active Active
- 2021-04-09 AU AU2021253674A patent/AU2021253674A1/en active Pending
- 2021-04-09 WO PCT/EP2021/059285 patent/WO2021204994A1/en not_active Ceased
- 2021-04-09 JP JP2022561400A patent/JP7794757B2/ja active Active
- 2021-04-09 CN CN202180027438.7A patent/CN115427068A/zh active Pending
- 2021-04-09 US US17/995,820 patent/US20230151106A1/en active Pending
- 2021-04-09 EP EP21716231.2A patent/EP4132564A1/en active Pending
- 2021-04-09 BR BR112022019038A patent/BR112022019038A2/pt not_active Application Discontinuation
- 2021-04-09 IL IL296701A patent/IL296701A/en unknown
- 2021-04-09 CA CA3176574A patent/CA3176574A1/en active Pending
- 2021-04-09 EP EP25220406.0A patent/EP4682171A3/en active Pending
- 2021-04-09 KR KR1020227038773A patent/KR20220166827A/ko active Pending
-
2025
- 2025-09-11 JP JP2025151221A patent/JP2026009900A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023521754A (ja) | 2023-05-25 |
| EP4682171A2 (en) | 2026-01-21 |
| DE202021004005U1 (de) | 2022-05-06 |
| BR112022019038A2 (pt) | 2022-11-01 |
| EP4682171A3 (en) | 2026-05-06 |
| CA3176574A1 (en) | 2021-10-14 |
| US20230151106A1 (en) | 2023-05-18 |
| WO2021204994A1 (en) | 2021-10-14 |
| EP4132564A1 (en) | 2023-02-15 |
| JP7794757B2 (ja) | 2026-01-06 |
| MX2022012600A (es) | 2023-02-15 |
| EP4707302A2 (en) | 2026-03-11 |
| KR20220166827A (ko) | 2022-12-19 |
| JP2026009900A (ja) | 2026-01-21 |
| CN115427068A (zh) | 2022-12-02 |
| AU2021253674A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026009900A (ja) | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ | |
| EP3864053B1 (en) | Treatment of rms by switching therapy | |
| US20240228647A1 (en) | Ofatumumab for treating multiple sclerosis in asian patients | |
| CA3229704A1 (en) | Ofatumumab for treating pediatric ms | |
| TW202300523A (zh) | 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB) | |
| BR122024017958A2 (pt) | Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| KR20250135226A (ko) | 자가면역 질환의 치료를 위한 항-cd38 항체 | |
| CN117015397A (zh) | 用于治疗狼疮的方法和组合物 | |
| HK40051003A (en) | Treatment of rms by switching therapy | |
| HK40051003B (en) | Treatment of rms by switching therapy | |
| CN117813328A (zh) | 用于治疗儿童ms的奥法妥木单抗 | |
| CN121843712A (zh) | 用于治疗多发性硬化症的组合物和方法 | |
| JP2024516019A (ja) | 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療 |